Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA, a clinical-stage biotech company focused on cancer immunotherapies, has announced participation in the H.C. Wainwright 26th annual global investment conference. The company’s portfolio, including the lead program lacutamab and collaborations with industry giants like AstraZeneca, showcases its commitment to leveraging the innate immune system to benefit cancer patients. Innate Pharma, with a presence in France and the US, is public on Euronext Paris and Nasdaq.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
